References
- Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. [Internet]. 2016 Dec 18;4(1):59. Availablefrom: https://doi.org/10.1186/s40425-016-0165-6.
- de Melo Gagliato D, Cortes J, Curigliano G, et al. Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. Biochim Biophys Acta - Rev Cancer. [Internet]. 2017 Dec;1868(2):527–537. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304419X17301397
- Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. [Internet]. 2015 Feb;26(2):259–271. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419313699
- Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. [Internet]. 1992 Apr;28(4–5):859–864. Available from: https://linkinghub.elsevier.com/retrieve/pii/095980499290134N
- Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. [Internet]. 2018 Jan;19(1):40–50. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147020451730904X
- Hamy A-S, Pierga J-Y, Sabaila A, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. [Internet]. 2017 Sep;28(9):2233–2240. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419352561
- Luen SJ, Salgado R, Dieci MV, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019 Feb;30(2):236–242.
- Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. [Internet]. 2020 May;31(5):569–581. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753420360324
- Luen SJ, Griguolo G, Nuciforo P, et al. On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. J Clin Oncol. [Internet]. 2019 May 20;37(15_suppl):574. Available from: https://doi.org/10.1200/JCO.2019.37.15_suppl.574.
- Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569.
- Gonzalez‐Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. [Internet]. 2020 Apr 9;250(5):667–684. Available from: https://doi.org/10.1002/path.5406.
- De Gramont A, Watson S, Ellis LM, et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol. [Internet]. 2015 Apr 25;12(4):197–212. Available from: http://www.nature.com/articles/nrclinonc.2014.202
- Amur S, LaVange L, Zineh I, et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther. [Internet]. 2015 Jul;98(1):34–46.
- Leptak C, Menetski JP, Wagner JA, et al. What evidence do we need for biomarker qualification? Sci Transl Med. [Internet]. 2017 Nov 22;9(417):eaal4599. Available from: https://doi.org/10.1126/scitranslmed.aal4599
- Denkert C, Wienert S, Poterie A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. [Internet]. 2016 Oct 1;29(10):1155–1164. Available from: http://www.nature.com/articles/modpathol2016109
- Wein L, Savas P, Luen SJ, et al. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol. [Internet]. 2017 Aug 3;7. Available from: https://doi.org/10.3389/fonc.2017.00156/full
- Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol. [Internet]. 2019 Jan 1;5(1):74. Available from: https://doi.org/10.1001/jamaoncol.2018.4224.
- Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. JNCI J Natl Cancer Inst. [Internet]. 2021 Feb 1; Available from: https://doi.org/10.1093/jnci/djab004/6125365
- Loi S, Adams S, Schmid P, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol. [Internet]. 2017 Sep;28:v608. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753420391055
- Füzéry AK, Levin J, Chan MM, et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. [Internet]. 2013 Dec 2;10(1):13.Available from: https://doi.org/10.1186/1559-0275-10-13.